Azrolid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azrolid

Azrolid: An Azalide Antibiotic Entity Overview

This section defines the identity and classification of Azrolid, whose active ingredient is Azithromycin, providing a concise, authoritative summary of its nature and general purpose.

Property Description
Active ingredient Azithromycin (INN)
Form Tablet, Capsule, Oral Suspension, Powder (Sachet)
Pharmacological class Macrolide Antibiotic (Azalide Subclass)
Common use Management of bacterial infections
Origin Semi-synthetic

What Type of Medicine is Azrolid?

Azrolid is a powerful anti-infective agent available as a prescription-only drug used to manage infections caused by susceptible bacteria. The medicine's active ingredient is Azithromycin (INN), which belongs to the macrolide antibiotic class, specifically categorized as an azalide. Azithromycin is recognized as an essential medicine, indicating its high clinical recognition for safety and efficacy in treating common bacterial pathogens.

The drug is recognized as a key source of Azithromycin, distinguishing it as a trusted entity for infectious disease management. Its use is clinically recognized for systemic action against various bacterial conditions, serving as a reliable alternative to older antibiotic generations.


Azithromycin: Composition, Origin, and Forms

The defining element of Azrolid is its core ingredient, Azithromycin, a semi-synthetic compound derived from a base macrolide structure. As a single-ingredient product, it combines the active substance with necessary inert excipients to ensure stability and proper delivery.

Azrolid is designed for the oral route of administration and is supplied in several common dosage forms to accommodate patient needs across various age groups. These forms include solid options, such as the tablet and capsule, and liquid preparations, such as the oral suspension and powder packaged in a sachet. The availability of the oral suspension is particularly beneficial for treating pediatric patients who require precise dosing and an easier method of intake.


How Azrolid is Different from Older Antibiotics

Azithromycin's distinction among antibiotics is attributed to its unique azalide structure. This modification is directly linked to the drug's remarkable ability to penetrate tissues and remain concentrated in the body for an unusually long period, with its terminal elimination half-life averaging about 68 hours.

This characteristic long half-life means Azithromycin can achieve therapeutic efficacy with a shorter treatment course and less frequent dosing compared to many conventional antibiotics, such as Erythromycin. This streamlined dosing schedule is a key differentiating factor that enhances patient convenience and improves adherence to the full regimen for managing susceptible bacterial infections.

Regulatory References

  1. Azithromycin Official Label and Information
  2. Azithromycin MedlinePlus Drug Information

What side effects are possible with Azrolid?

Possible Side Effects and Safety Information

The information presented here reflects the documented safety profile and officially reported adverse reactions for Azrolid, strictly based on regulatory documents from government health authorities.

Serious and Clinically Significant Adverse Reactions

The most serious documented risks, which may be rare, include potentially fatal events and severe organ system toxicity. Patients should be aware of risks such as:

  • Cardiac Events: Prolongation of the QT interval, Torsades de Pointes, and rare reports of cardiovascular death. The risk for these serious events has been noted to be greater during the first five days of use.
  • Hepatotoxicity: Severe, sometimes fatal, hepatic dysfunction and cholestatic jaundice.
  • Severe Hypersensitivity Reactions: Anaphylaxis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Discontinuation is required if signs of these reactions occur.
  • Clostridioides difficile-Associated Diarrhea (CDAD): May occur with nearly all antibacterial agents.

Common Adverse Reactions

The most commonly reported adverse reactions are primarily gastrointestinal, including:

Classification Frequency Examples
Common 3% to 18% Nausea, Abdominal Pain, Vomiting
Most Common 5% to 14% Diarrhea

Population-Specific Safety Considerations

Specific warnings address certain groups or pre-existing conditions:

  • Cardiac Risk: Caution is required in patients with pre-existing QT prolongation, bradyarrhythmias, congenital long QT syndrome, or uncompensated heart failure. The elderly may have increased susceptibility.
  • Myasthenia Gravis: Use may exacerbate symptoms of muscle weakness in individuals with Myasthenia Gravis.
  • Neonatal Use: There have been reports of Infantile Hypertrophic Pyloric Stenosis (IHPS) following administration to neonates (treatment up to 42 days of life).

Safety Restrictions

Azrolid is contraindicated in individuals with known hypersensitivity to the drug, erythromycin, or any macrolide/ketolide drug. It is also restricted in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of the drug.

Overdose and Emergency Response

Officially documented manifestations of Azrolid (Azithromycin) overdosage are generally similar to adverse reactions reported at therapeutic doses, but occur with increased severity. Symptoms primarily involve marked gastrointestinal effects, including severe nausea, vomiting, and abdominal pain, along with severe diarrhea.

A critical risk documented in regulatory labeling is the potential for Life-Threatening Cardiotoxicity. Overdosage may lead to prolongation of the QT interval and the development of the potentially fatal irregular heart rhythm, Torsades de pointes. Severe hepatotoxicity and liver damage have also been reported in the context of high systemic exposure.

Immediate medical attention is required if an overdose is suspected or if symptoms such as an irregular heartbeat, shortness of breath, dizziness, or fainting occur. Due to the serious cardiovascular risks, management in a clinical setting requires continuous ECG monitoring and the application of general symptomatic and supportive measures, as no specific antidote is known.

Regulatory documents specify that patients with severe renal impairment exhibit significantly increased systemic drug exposure, indicating a higher risk of toxicity. In neonates, severe vomiting that can indicate Infantile Hypertrophic Pyloric Stenosis (IHPS) requires immediate medical evaluation and contact with a healthcare professional.

Therapeutic Uses of Azrolid

Azrolid is commonly applied in clinical settings that involve acute or unstable symptom patterns caused by susceptible bacterial infections. The therapeutic domains for the medication commonly include use in addressing infections across the respiratory tract, ear, throat, skin, and urogenital system.

The medication is relevant in conditions characterized by periods of heightened symptoms, such as Community-Acquired Pneumonia (CAP), acute exacerbations of chronic bronchitis, pronounced sore throat, acute otitis media (ear infection), certain sexually transmitted infections (STIs), and uncomplicated skin infections. It helps address symptom clusters that may become intense or disruptive, including persistent coughing, significant phlegm production, and acute localized discomfort. The treatment may contribute to easing the overall symptom load, supporting improved comfort during symptomatic periods.

It may assist with maintaining functional stability and contributes to supporting the patient during difficult episodes by helping to ease distress. It is also applied in specialized scenarios for the long-term prevention of Mycobacterium avium Complex (MAC) disease in vulnerable patients.


Quick Fact: Focus on Acute Symptom Relief The medication is commonly used when symptoms related to inflammatory or irritative states become temporarily overwhelming. It may be applied to support relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Azrolid?

The eligibility for using Azrolid (Azithromycin) is determined by regulatory guidelines based on patient history, age, and pre-existing conditions. These rules define who is formally contraindicated from using the medicine and who requires special caution.


Absolute Non-Eligibility (Contraindications)

Azrolid must not be used by patients who have a known history of hypersensitivity (allergic reaction) to azithromycin, any other macrolide or ketolide antibiotic, or a history of cholestatic jaundice or hepatic dysfunction previously associated with azithromycin use.


Eligibility by Age Group and Condition

Population/Condition Eligibility Status (Official Regulatory)
Infants Safety and effectiveness not established for those under 6 months of age.
Older Adults Caution advised due to increased susceptibility to certain cardiac arrhythmias.
Severe Liver Disease Use is not recommended due to the liver's role in drug elimination.
Severe Renal Impairment Caution advised for those with severe kidney issues (GFR <10 mL/min).
Proarrhythmic Conditions Caution advised for conditions like known QT prolongation or clinically relevant bradycardia.

Pregnancy and Lactation

Use in pregnancy is restricted and should occur only if the benefit clearly outweighs the risk. During lactation, use is generally considered acceptable, but monitoring the infant for gastrointestinal symptoms is advised.

What should I know about interactions with other medicines?

Azrolid Interactions with other medicines and products

Official government regulatory sources establish specific restrictions and required separations for co-administering Azrolid (Azithromycin) with certain medicinal products and substances.

Contraindicated Combinations

Co-administration is formally contraindicated with Ergot Alkaloids (such as Ergotamine and Dihydroergotamine) due to the risk of acute ergotism, a restriction derived from the known effects of the macrolide class. Co-administration with Pimozide is also contraindicated due to the potential for an additive effect that prolongs the QT interval and increases the risk of cardiac arrhythmias.

Pharmacokinetic and Pharmacodynamic Interactions

The regulatory profile documents potential effects on the systemic exposure of co-administered drugs. Concurrent use with P-glycoprotein (P-gp) substrates like Digoxin may lead to increased systemic exposure of the P-gp substrate. Similarly, Azrolid co-administration has been reported to significantly increase the concentration ( Cmax and AUC) of Ciclosporin. Conversely, co-administration with Nelfinavir results in a substantial increase in Azithromycin exposure.

Pharmacodynamically, Azrolid may have an additive effect on the QT interval when used with other QT-prolonging products. Post-marketing reports also note potentiated anticoagulation when co-administered with Coumarin-type oral anticoagulants such as Warfarin.

Timing and Food Restrictions

Administration of Azrolid must be separated from Aluminum- or Magnesium-containing Antacids by at least one hour before or two hours after the antacid dose. This timing rule is necessary because antacids reduce the peak plasma concentration ( Cmax) of Azithromycin. For patients with hepatic impairment, interactions with hepatically eliminated drugs may be more clinically significant as the liver is the primary route of Azrolid's elimination.

Mechanism of Action

️ How Azrolid Works

Azrolid acts through two distinct mechanistic domains: directly inhibiting bacterial protein synthesis and modulating the host's inflammatory response.


Direct Inhibition of Microbial Protein Synthesis

This mechanism is centered on the bacterial 50S ribosomal subunit, the biological target where the drug acts as a precise inhibitor. Azrolid binds to the 23S ribosomal RNA (rRNA) component, physically blocking the nascent peptide exit tunnel and arresting the crucial translocation step. This molecular action triggers a cascade that results in the cessation of bacterial replication, a key physiological change that reduces the pathogen load.


Modulation of Host Inflammatory Mediators

Separate from its direct action on bacteria, Azrolid also functions as a modulator within host inflammatory pathways. The drug accumulates in immune cells like phagocytes and alters their internal signaling, which leads to the reduced release of proinflammatory cytokines (e.g., IL-8). This mechanism leads to the attenuation of inflammatory mediator release, which is a physiological process that reduces the magnitude of the tissue reaction caused by the underlying biological processes.

Dosage and Administration Information

How Azrolid is Used: Official Administration Guidelines

Azrolid (Azithromycin) must be used strictly according to established dosing and administration guidelines. The medication is primarily available for oral intake, but an intravenous (IV) infusion form is available for initial therapy in specific acute situations.

Administration is typically once daily over a short course, often involving a total dose of 1500 mg administered over three days (500 mg once daily) or five days (Day 1: 500 mg; Days 2–5: 250 mg once daily).


Official Administration and Dosing Principles

Usage Constraint Instruction
Route & Frequency Oral or IV; administered once daily
Timing (Oral) Tablets and Oral Suspension may be taken with or without food. Capsules must be taken at least 1 hour before or 2 hours after a meal.
Special Dosing A single 1000 mg dose is approved for certain infections. For prophylaxis of MAC, the dose is 1200 mg once weekly.
IV Infusion Rule Must be given as a slow intravenous infusion over a period of at least 60 minutes. It must not be given as a bolus injection.
Pediatric Dosing Dosing is determined by the child's body weight (mg/kg) and specific regimen.
Missed Dose Rule If the missed dose is within 12 hours, take it immediately; otherwise, skip the missed dose and resume the normal schedule. Do not take a double dose.

No dose adjustment is typically required for mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azrolid

This overview describes the types of clinical studies that have been conducted for Azrolid (Azithromycin) and the research questions they addressed, drawing on official regulatory and peer-reviewed scientific sources. It focuses on the available evidence structure without providing medical guidance or treatment advice.


Evidence for Use in Community-Acquired Pneumonia (CAP)

Research on Azrolid for CAP primarily involves Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies focused on both adult patients and separate trials for children. The research examined outcomes related to physical discomfort and systemic imbalance, such as achieving a defined monitored condition status and the time to change in fever. Findings describe patterns observed in the studies related to the changes in bacterial status of common causes of CAP. Long-term outcomes, such as the rate of recurrence, are not consistently captured in the primary RCTs.


Evidence for Use in Acute Otitis Media (AOM)

The evidence base for acute ear infections relies heavily on Comparative Clinical Trials conducted in pediatric populations. Studies explored outcomes related to physical discomfort and episodic changes, such as the changes in ear-related signs and symptoms. The research describes patterns observed in the study populations related to monitored clinical response rates at short-term follow-up visits. Follow-up durations were limited in many of the primary studies. Comparative evidence against certain newer standard-of-care antibiotics used for AOM appears to be less established.


Evidence for Chronic Respiratory Disease Exacerbation Prevention

The research on using Azrolid for the long-term prevention of flare-ups in conditions like Chronic Obstructive Pulmonary Disease (COPD) is supported by large, Long-term Randomized Controlled Trials. The research examined outcomes reflecting daily functioning, such as the rate of exacerbations and changes in patient-reported outcomes. Studies monitored responses over defined time intervals and reported patterns related to the frequency of exacerbation events compared to groups receiving an inactive substance (placebo). However, the long-term effects are not fully established, particularly concerning the non-infectious outcomes tracked during extended use, such as changes in auditory and cardiovascular function, which requires ongoing data collection. The results apply only to the populations studied (those with frequent exacerbations).

Key Studies & References Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents - Disseminated Mycobacterium avium Complex

Frequently Asked Questions (FAQ)

Common questions about Azrolid (FAQ)


Q: Is Azrolid safe to use if I have an existing heart condition?

Official warnings describe caution as necessary for individuals with certain pre-existing heart conditions. These conditions include an abnormally slow heart rhythm (bradyarrhythmia) or uncompensated heart failure. The elderly population may also have increased susceptibility to these cardiovascular effects.

Q: Does Azrolid have a risk of causing allergic reactions?

Yes, severe allergic reactions, or hypersensitivity, are documented risks associated with Azrolid. Official documents list a known allergy to Azrolid or any macrolide antibiotic as a formal contraindication.

Serious reactions such as anaphylaxis and angioedema are described in the regulatory safety profile.

Q: What is the risk of a serious skin reaction with Azrolid?

Serious skin reactions are documented in the official safety profile for this medicine. These include rare, severe conditions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS. Official information states that the drug should be discontinued if signs of these reactions appear.

Q: Can I take Azrolid if I am pregnant or planning to be?

Regulatory guidance for use during pregnancy indicates that it should be reserved for situations where the potential benefit to the patient clearly justifies the potential risk. This restriction is based on an official assessment of the available evidence and regulatory classification.

Q: What is known about using Azrolid while breastfeeding?

Official regulatory documents confirm that the medicine is excreted into human milk. While use is generally considered acceptable, monitoring the infant is advised.

The official recommendation is for monitoring the infant for potential gastrointestinal effects, such as diarrhea or vomiting.

Q: How is Azrolid eliminated from the body?

According to the official product information, Azrolid is primarily eliminated from the body through the bile, a process known as hepatic excretion. The medicine is documented to persist in the body for a relatively long period, with its elimination half-life averaging approximately 68 hours.

Q: Why are there warnings about Azrolid and abnormal heart rhythm?

The warnings are related to the medicine's potential to affect the heart’s electrical system. This effect, called QT interval prolongation, is associated with an increased risk of a specific, serious irregular heart rhythm called Torsades de Pointes.

Q: What is the difference between an allergy and a side effect with Azrolid?

An allergy (hypersensitivity) is a severe, immune-mediated reaction that makes future use of the drug formally contraindicated. A side effect (adverse reaction) is a known, non-immune-mediated consequence of the drug, such as nausea or abdominal pain, which may or may not require discontinuation.

Q: Is Azrolid considered a broad-spectrum medicine?

According to microbiology data in official documents, Azrolid is classified as having activity against a wide range of bacteria. This includes certain Gram-positive and Gram-negative organisms, as well as atypical bacteria.

Q: How is Azrolid different from other similar medicines in the same class?

Azrolid (Azithromycin) is chemically categorized as an azalide, which is a unique subclass of macrolides. This structure gives it a remarkably long elimination half-life of around 68 hours.

This characteristic is linked to the possibility of shorter treatment courses and less frequent dosing compared to older macrolide antibiotics.

Q: Does Azrolid start working right away, or does it take a few days?

The medicine starts the process of working in the body immediately after the first dose is taken. However, studies generally describe the onset of clinical response, meaning the noticeable improvement of symptoms, as occurring within 2 to 3 days of starting therapy.

Q: Does Azrolid interact with common pain relievers like ibuprofen?

Official regulatory documents indicate that Azrolid is not expected to interact significantly with common over-the-counter pain relievers. This is because the medicine does not significantly affect the primary metabolic pathway used by non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.

Q: Are there any major food or drink items that should be avoided with Azrolid?

The official product information specifies a rule for Azrolid capsules, which must be taken without food for proper absorption. However, outside of this specific timing rule and the required separation from antacids, official regulatory labels do not list any specific food or drink items, such as grapefruit juice, that must be avoided.

Q: Does Azrolid affect how birth control pills work?

Regulatory sources confirm that Azrolid is generally not associated with reducing the effectiveness of oral contraceptives, often called birth control pills.

Q: If I feel better, is it okay to stop taking Azrolid before the full course is finished?

Patient information provided by regulatory bodies emphasizes the importance of taking the full prescribed amount. Completing the full course is described as important to help eliminate the infection and reduce the chance of remaining bacteria developing resistance to the medication.

Q: Is Azrolid related to penicillin or sulfa drugs?

No, Azrolid belongs to the macrolide class of antibiotics. Regulatory documents clarify that it is not chemically related to either the penicillin or sulfa drug classes.

Q: Has Azrolid been approved in different countries?

The active ingredient in Azrolid, Azithromycin, is recognized globally. It is listed on the World Health Organization's List of Essential Medicines and has received approval from numerous governmental health agencies worldwide, including the EMA in Europe and Health Canada.

Q: Is there a generic version of Azrolid available?

The active ingredient in Azrolid is Azithromycin. Following patent expiration, this ingredient became widely available as a generic medicine under its chemical name.

Q: Does Azrolid interact with alcohol consumption?

Regulatory information and patient-facing guides typically indicate that there is no known specific negative interaction between Azrolid and moderate consumption of alcohol.

Q: What are the signs of an overdose with Azrolid?

The symptoms described following an overdose are consistent with the known side effects, which may become severe. These symptoms include intense nausea, vomiting, diarrhea, and in some documented cases, reversible hearing loss.

Q: Can Azrolid cause dizziness or affect my ability to drive?

Official regulatory documents list dizziness as an infrequent adverse reaction. Because of this and other possible effects like vision disturbances, official regulatory documents advise caution regarding the potential for temporary impairment of the ability to drive or operate machinery.

Q: What should I do if I experience diarrhea while taking Azrolid?

While mild diarrhea is listed as a common side effect, the official warnings highlight that severe, persistent diarrhea can be a sign of a serious condition. If diarrhea is severe or persistent, seeking immediate attention is advised to assess for Clostridioides difficile-Associated Diarrhea (CDAD).

Q: Is Azrolid a type of steroid or hormone medicine?

No. Azrolid is strictly classified as an anti-infective agent and specifically belongs to the macrolide antibiotic class. It does not contain any steroid or hormone compounds.

Q: Can Azrolid interact with certain vitamins or herbal supplements?

Regulatory labels extensively document drug-drug interactions. However, official information does not report significant negative interactions between Azrolid and common, standard doses of vitamins or minerals.

Q: Why is it important to complete the full course of Azrolid?

The primary regulatory rationale for completing the full course is to support the complete eradication of the bacteria causing the infection. This action is critical to prevent the remaining, partially treated bacteria from developing resistance to the medication.

Q: Are long-term side effects associated with Azrolid use?

Studies involving the use of Azrolid for extended periods (such as for flare-up prevention) documented adverse events related to auditory and cardiovascular function. This information indicates that monitoring for such effects may be necessary during extended treatment periods.

Q: Is Azrolid effective against viruses?

No. Azrolid is an antibiotic, meaning its mechanism of action is limited to inhibiting bacterial protein synthesis. It is not effective against illnesses caused by viruses.

Q: Can Azrolid affect blood sugar levels?

While not a common side effect, regulatory documents list the occurrence of hypoglycemia (abnormally low blood sugar) as a rare adverse reaction. This information is based on reports collected during post-marketing surveillance.

Q: What does the term 'Azrolid resistance' mean?

Regulatory microbiology sections explain that resistance occurs when a bacterium develops the ability to defeat the medicine. This happens when the bacteria either prevents the drug from binding to its ribosomal target or actively expels the drug from the cell, rendering the medication ineffective.

Q: Can Azrolid cause issues with sleep?

Official regulatory documents list insomnia (difficulty falling or staying asleep) as an infrequent adverse reaction. This information is based on reports collected during clinical trials and post-marketing surveillance.

Q: Does Azrolid carry a risk of tendon problems?

No. Unlike certain other classes of antibacterial medicines, the official regulatory warnings for Azrolid (Azithromycin) do not include a risk of tendon rupture or tendonitis.

Q: Are there specific lab tests required before or during treatment with Azrolid?

While routine laboratory testing is not universally required, regulatory documents advise caution for patients with severe liver impairment. This caution suggests that the need for liver function testing may be assessed prior to initiating use in this patient group.

How should Azrolid be stored and disposed of?

Official Storage and Handling Requirements

Azrolid (Azithromycin) must be stored strictly according to regulatory specifications to ensure stability.

Requirement Storage Conditions
Temperature (Tablets/Powder) Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F).
Temperature (Suspension) Store the reconstituted liquid between 5 C and 30 C (41 F to 86 F); do not freeze [Source: 1.1, 1.2].
Stability Period The standard oral suspension must be discarded after 10 days of mixing, even if some medicine remains [Source: 1.2, 1.5].
Protection Keep the medicine in its original container, tightly closed, and protect it from excessive heat, light, and moisture [Source: 1.1, 1.2].
Child Safety Keep out of the sight and reach of children [Source: 1.2].

Official Disposal Instructions

Unused or expired Azrolid must be disposed of in accordance with local regulations.

  • Preferred Method: Utilize authorized drug take-back programs or mail-back services where available [Source: 2.2, 2.6].
  • Household Disposal: If a take-back option is unavailable, the drug should be mixed with an undesirable substance (e.g., used coffee grounds), placed in a sealed bag or container, and disposed of in the household trash [Source: 2.2, 2.7].
  • Flushing: Do not flush the medicine down the toilet or sink unless specific instructions on the label advise this action [Source: 2.6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azrolid found in:

A-Z Index: